Advertisement

Journal of Neurology

, Volume 266, Issue 5, pp 1270–1271 | Cite as

Two cases of diabetes mellitus type 1 after alemtuzumab treatment for multiple sclerosis: another probable secondary autoimmune disease

  • Stephan RichterEmail author
  • Bert Wagner
  • Elisabeth Gulowsen Celius
Letter to the Editors

Dear Sirs,

Alemtuzumab (ATZ) is an established highly effective treatment in relapsing-remitting multiple sclerosis (RRMS) [1, 2, 3]. Secondary autoimmune disorders in MS patients treated with alemtuzumab have been reported in a frequency of about 40% for thyroid disorders, 3% for thrombocytopenic purpura (ITP) and below 0.3% for glomerulonephritis [4]. So far, one case of diabetes type 1 (T1D) as a possible secondary autoimmune disease following alemtuzumab treatment has been published [5].

We report on two patients who had an acute increase in their blood glucose level several months after the second course of alemtuzumab. In both cases, a diagnosis of T1D was made. In addition, thyroid disorders occurred in both cases over the course of time.

Case #1

A 37-year-old male patient had the first symptoms of RRMS at the age of 19. He had no history of autoimmune disorders, but his mother has MS reaching immobility at the age of 50. During interferon therapy, he experienced about one...

Notes

Compliance with ethical standards

Conflicts of interest

Stephan Richter has received honoraria for advisory board councils and travel expenses for attending meetings from Biogen, Celgene, Genzyme, Merck, Novartis and Roche. Bert Wagner has received honoraria for advisory board councils and travel expenses for attending meetings from Biogen, Genzyme, Merck, Novartis and Roche. Elisabeth G. Celius has received honoraria for advisory boards and/or speaker honoraria from Biogen, Merck, Roche, Novartis, Genzyme and Teva, and unrestricted research grants from Novartis and Genzyme.

Ethical standards

This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. 1.
    Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA (2012) Investigators C-MI. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomized controlled phase 3 trial. Lancet 380:1819–1828CrossRefGoogle Scholar
  2. 2.
    Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA (2012) Investigators C-MI. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380:1829–1839CrossRefGoogle Scholar
  3. 3.
    Havrdova E, Horakova D, Kovarova I (2015) Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use. Ther Adv Neurol Disord 8:31–45CrossRefGoogle Scholar
  4. 4.
    Coles AJ, Cohen JA, Fox EJ, Giovannoni G, Hartung HP, Havrdova E, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Chirieac MC, Jody D, Xenopoulos P, Hogan RJ, Panzara MA, Arnold DL (2017) Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. Neurology 89:1117–1126CrossRefGoogle Scholar
  5. 5.
    Malmeström C, Andersson BA, Lycke J (2014) First reported case of diabetes mellitus type 1 as a possible secondary autoimmune disease following alemtuzumab treatment in MS. J Neurol 261:2016–2018CrossRefGoogle Scholar
  6. 6.
    Wertman E, Zilber N, Abramsky O (1992) An association between multiple sclerosis and type I diabetes mellitus. J Neurol 239:43–45CrossRefGoogle Scholar
  7. 7.
    Marrosu MG, Cocco E, Lai M, Spinicci G, Pischedda MP, Contu P (2002) Patients with multiple sclerosis and risk of type 1 diabetes mellitus in Sardinia, Italy: a cohort study. Lancet 359:1461–1465CrossRefGoogle Scholar
  8. 8.
    Hussein WI, Reddy SS (2006) Prevalence of diabetes in patients with multiple sclerosis. Diabetes Care 29:1984–1985CrossRefGoogle Scholar
  9. 9.
    Ruck T, Pfeuffer S, Schulte-Mecklenbeck A, Gross CC, Lindner M, Metze D, Ehrchen J, Sondermann W, Pul R, Kleinschnitz C, Wiendl H, Meuth MD, Klotz SG (2018) L. Vitiligo after alemtuzumab treatment, Secondary autoimmunity is not all about B cells. Neurology 91:e2233–e2237CrossRefGoogle Scholar
  10. 10.
    Della Valle P, Coluccia A, Martinelli V, Comi G, D´Angelo A, Moiola L (2018) Acquired haemophilia a as a secondary autoimmune disease after alemtuzumab treatment in multiple sclerosis: a case report. Mult Scler Relat Disord 27:403–405Google Scholar
  11. 11.
    Hoffman BM, Zeid NA, Alam U, Caress JB (2019) Lambert-Eaton myasthenic syndrome associated with alemtuzumab administration. Mult Scler Relat Disord 27:131–132CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Neuro-MVZ (MIND) StuttgartStuttgartGermany
  2. 2.Department of NeurologyOslo University HospitalUllevål, Boks, Nydalen, OsloNorway
  3. 3.Institute of Clinical MedicineUniversity of OsloOsloNorway

Personalised recommendations